Values First Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Values First Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,904	Closed	-$1.01M	–	165
2022 Q2	$1.01M	Buy	6,904 +2,587	+60%	+$330K	0.71%	47
2022 Q1	$512K	Buy	4,317 +315	+8%	+$39.3K	0.32%	90
2021 Q4	$552K	Sell	4,002 -91	-2%	-$11.6K	0.33%	93
2021 Q3	$569K	Sell	4,093 -2,398	-37%	-$299K	0.37%	85
2021 Q2	$630K	Buy	6,491 +854	+15%	+$69.3K	0.43%	83
2021 Q1	$385K	Buy	5,637 +768	+16%	+$62.1K	0.28%	110
2020 Q4	$417K	Buy	4,869 +89	+2%	+$7.54K	0.33%	99
2020 Q3	$311K	Sell	4,780 -1,895	-28%	-$124K	0.29%	114
2020 Q2	$488K	Sell	6,675 -1,430	-18%	-$76.1K	0.48%	72
2020 Q1	$276K	Buy	+8,105	New	+$371K	0.33%	93

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Values First Advisors's BHVN Position: Q3 2022 in Review

Values First Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 6,904 shares — an estimated $1.01M sold.

Values First Advisors first reported a position in BHVN in Q1 2020 and held it in 10 quarters. The position peaked at $1.01M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Values First Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Values First Advisors sold 6,904 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $1.01M.
Values First Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 10 quarters.
Values First Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.01M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Values First Advisors's 13F filing for Q3 2022, filed 2 Dec 2022.